GLPwatch

Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.

Diabetes Metab Syndr Obes · 2023

Last updated 2026-05-28

Newer weight-loss medications like liraglutide, semaglutide, orlistat, and the combinations phentermine/topiramate and bupropion/naltrexone have been approved by the FDA to help manage obesity. These drugs have shown promising results in reducing weight and have tolerable safety profiles. Tirzepatide, which is still under evaluation, is also discussed as a potential option.

AI summary of the abstract below.

JournalDiabetes Metab Syndr Obes, 2023
Citations24
Relative citation ratio3.12
NIH percentile85
Molecules
Conditions studied Obesity

Abstract

Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.

Verbatim abstract via PubMed 37337548 ↗